Innovative glaucoma therapy. Glaucoma therapy with topical carbonic anhydrase inhibitors;Innovative glaukomtherapie: Glaukomtherapie mit lokalen karboanhydrasehemmern

Ophthalmologe

Volumn 98, Issue 10, 2001, Pages 929-933

  Herkel, U ^a   Pfeiffer, N ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Brinzolamide; Dorzolamide; Glaucoma; Ocular perfusion; Topical carbonic anhydrase inhibitors

Indexed keywords

BRINZOLAMIDE; CARBONATE DEHYDRATASE INHIBITOR; DORZOLAMIDE;

DRUG STRUCTURE; EYE BLOOD FLOW; GLAUCOMA; HEMODYNAMICS; HUMAN; INTRAOCULAR PRESSURE; REVIEW; RISK BENEFIT ANALYSIS;

EID: 0034783018     PISSN: 0941293X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003470170039     Document Type: Review

References (30)

1. Irreversible corneal decompensation in patients treated with topical dorzolamide
2. Decrease in intraocular pressure in man by a carbonic anhydrase inhibitor, diamox
3. Okuläre hämodynamik und gesichstfeld beim glaukom unter dorzolamid-therapie
4. Nephrolithiasis with Dorzolamide
5. Preclinical overview of brinzolamide
6. Comparison of latanoprost monotherapy to dorzolamide combined with timolol in patients with glaucoma and ocular hypertension. A 3-month randomised study
7. Topical dorzolamide increases optic nerve oxygen tension in the pig
8. Relationship between ocular perfusion pressure and retrobulbar blood flow in patients with glaucoma with progressive damage
9. Dorzolamide and corneal recovery from edema in patients with glaucoma orocular hypertension
10. Effect of brinzolamide and dorzolamide on aqueous humor flow in human eyes
11. Irreversible corneal decompensation in patients treated with topical dorzolamide
12. The long-term safety and efficacy of brinzolamide 1.0% (azopt) in patients with primary open-angle glaucoma or ocular hypertension
13. Dorzolamide effect on ocular blood flow
14. The European Glaucoma Prevention Study. Baseline Description of the Participants
15. A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension:a 3 month, randomised study
16. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension
17. Lokaler karboanhydrasehemmer dorzolamid: Entwicklung und eigenschaften
18. Dorzolamide: Development and clinical application of a topical carbonic anhydrase inhibitor
19. Effect of topical dorzolamide on optic nerve head blood flow
20. Peripapillary focal retinal arteriolar narrowing in open angle glaucoma
21. The efficacy and safety of brinzolamide 1% ophthalmic suspension (azopt((R))) as a primary therapy in patients with open-angle glaucoma or ocular hypertension
22. Ocular pulse amplitude, intraocular pressure and beta blocker/carbonic anhydrase inhibition in combined therapy of primary open-angle glaucoma
23. Sterile mucopurulent conjunctivitis associated with the use of dorzolamide eyedrops
24. Adjunctive therapy with brinzolamide 1% ophthalmic suspension (azopt((R))) in patients with open-angle glaucoma or ocular hypertension maintained on timolol therapy
25. Clinical efficacy and safety of brinzolamide (Azopt),a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension
26. Ocular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution. results from two multicenter comfort studies
27. Dose-Response Evaluation of the Ocular Hypotensive Effect of Brinzolamide Ophthalmic Suspension (Azopt((R)))
28. Optic nerve oxygen tension in pigs and the effect of carbonic anhydrase inhibitors
29. Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocular pressure
30. Additive effect of latanoprost to the combination of timolol and dorzolamide